Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03211793
Other study ID # MANUS
Secondary ID 2015-000168-32
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 6, 2021
Est. completion date November 1, 2024

Study information

Verified date December 2023
Source UMC Utrecht
Contact Femke van Rhijn, MD
Phone 0031887557329
Email f.c.c.brouwer-3@umcutrecht.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The MANUS Trial aims to examine the safety, feasibility and potential efficacy of intramuscularly injected allogeneic mesenchymal stromal cells as treatment for digital ulcers of systemic sclerosis.


Description:

The MANUS Trial is a randomized double-blind, placebo-controlled clinical trial. Patients with systemic sclerosis (SSc) and digital ischemia with intractable ischemic digital ulcers refractory to conventional treatments are eligible to participate. 20 participants will be randomised (1:1) to undergo intramuscular injection (8 sites) of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSC) (45-50*10^6) or placebo in the most affected limb. Main study parameters/endpoints: The primary outcome is the toxicity of the treatment at 12 weeks after MSC administration, defined as 1. Local toxicity, including signs of local inflammation (swelling, warmth, impairment of function), worsening of ulcers or new ulcers or hematomas after MSC administration 2. Other adverse events, graded according to the Common Terminology Criteria for Adverse Events version 4.0, expressed as maximum grade toxicity per organ system. Secondary outcome measures are: number of serious adverse events, pain and disability parameters; healing, time to healing and reduction of new ischemic digital ulcers; modified Rodnan skin score; Scleroderma Health Assessment Questionnaire (S-HAQ) including visual analogue scales (VAS) for scleroderma-specific symptoms; Quality-of-life (SF-36, EuroQol (EQ-5D); Cochin hand function score. We will also evaluate changes in capillary morphology and architecture using capillaroscopy; biochemical parameters; markers for endothelial activation and injury, inflammation, oxidative stress, circulating cells including endothelial cells, hematopoietic and endothelial progenitor cells, cytokines and growth factors, immunological responses. Follow-up visits will be scheduled at 48 hours and 2, 4, 8, 12, 24 and 52 weeks post-treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date November 1, 2024
Est. primary completion date November 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Established diagnosis of SSc according to the 2013 ACR/EULAR criteria - At least one active digital ulcer (painful area, >2 mm in diameter with visible depth and loss of dermis) refractory to intravenous prostacyclins - 'Refractory to prostacyclins' is defined as - Worsening of ulcer(s) within 1 month after prostacyclins iv - No improvement of ulcer(s) after 2 months after prostacyclins iv, as judged by the referring physician - Recurrence of exactly the same ulcer(s) (same location) within 3 months after prostacyclins iv - Written informed consent Exclusion Criteria: - Ulcer with underlying calcinosis (ruled out by X-ray prior to screening/inclusion) - History of neoplasm or malignancy in the past 10 years - Pregnancy or unwillingness to use adequate contraception during study - Serious known concomitant disease with life expectancy <1 year - Uncontrolled hypertension - Uncontrolled acute or chronic infection with systemic symptoms (e.g. fever) - Follow-up impossible

Study Design


Intervention

Drug:
Mesenchymal stromal cells
8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
Other:
Placebo
8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).

Locations

Country Name City State
Netherlands Universitair Medisch Centrum Utrecht Utrecht

Sponsors (2)

Lead Sponsor Collaborator
UMC Utrecht ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity of the treatment Toxicity of the treatment is defined as 1. Local toxicity, including signs of local inflammation (swelling, warmth, impairment of function), worsening of ulcers or new ulcers or hematomas after MSC administration 2. Other adverse events, graded according to the Common Terminology Criteria for Adverse Events version 4.0, expressed as maximum grade toxicity per organ system. 12 weeks after MSC administration
Secondary Serious adverse events Any treatment-related serious adverse events (SAE) defined as events leading to hospitalization, death, or persistent or significant disability. To establish the presence or absence of a causal relationship, the World Health Organisation guidelines for pharmacovigilance will be followed. 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Change in perceived pain based on the Numerical Rating Scale Change in pain as assessed using the Numerical Rating Scale, 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ) Change in pain as assessed using the digital ulcer visual analogue scale (part of the S-HAQ). 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Change in perceived pain based on the pain VAS ( part of the S-HAQ) Change in pain as assessed using the pain VAS (S-HAQ), use of analgesics. 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Change in perceived pain based on the use of analgesics. Change in pain as assessed by analyzing the use of analgesics. 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Quality of life - SF-36 SF-36 questionnaire. 12, 24 and 52 weeks after MSC administration
Secondary Quality of life - Euroqol EuroQol questionnaire 12, 24 and 52 weeks after MSC administration
Secondary Disability Assessed with the HAQ-DI questionnaire. 12, 24 and 52 weeks after MSC administration
Secondary Hand function Cochin Hand Function Score 12, 24 and 52 weeks after MSC administration
Secondary Number (and change in number) of digital ulcers 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Healing of digital ulcers Healing of ulcers is defined as complete epithelialization, regardless of residual pain. This will be established using sequential pictures in addition to the clinical examination. 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Ulcer size Using sequential pictures, ulcer area and circumference will be measured. 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Time to healing of digital ulcers 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Need to alter medication regime The need to alter the medication regime as determined by the patient's attending rheumatologist. 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
Secondary Modified Rodnan Skin Score 12, 24 and 52 weeks after MSC administration
Secondary Severity of Raynaud's symptoms Raynaud Condition Score 12 , 24 and 52 weeks after MSC administration
Secondary Changes in capillary morphology and architecture as visualized with video-assisted nailfold capillaroscopy by a trained investigator. The images will be scored by a certified rheumatologist and a trained investigator. 2, 12, 24 weeks and 52 weeks after MSC administration
Secondary Changes in laboratory parameters A range of haematological and chemical parameters will be measured for safety assessment. Additionally, serum, plasma and peripheral blood mononuclear cells will be collected and stored for analysis at a later time point. Samples will be analysed and used to assess markers for endothelial activation and injury, proangiogenic factors, inflammation and oxidative stress. The presence of HLA-antibodies will be determined as well. 48 hours, 2, 4, 8, 12 weeks after MSC administration
Secondary Changes in circulating cell populations Circulating cell populations will be studied by immunofluorescence labelling and analysis using fluorescence assisted cell sorting (FACS Canto machine). 48 hours, 2, 4, 8, 12 weeks after MSC administration
See also
  Status Clinical Trial Phase
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT04300426 - Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) Phase 2
Recruiting NCT06058091 - RY_SW01 Cell Injection Therapy in Systemic Sclerosis Phase 1/Phase 2
Recruiting NCT04356755 - Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma. Phase 2
Suspended NCT06210945 - Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis Phase 2
Not yet recruiting NCT05947682 - Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis N/A
Not yet recruiting NCT04303208 - Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis N/A
Not yet recruiting NCT05177380 - Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis N/A
Recruiting NCT02551042 - CSL Behring Sclero XIII Phase 2
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Completed NCT01933334 - Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Phase 2
Completed NCT01468792 - Hemodynamic Changes in Connective Tissue Disease N/A
Terminated NCT00848107 - Open-Label Study of Oral Treprostinil in Digital Ulcers Phase 2
Completed NCT00984932 - Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension Phase 3
Completed NCT00074568 - Scleroderma Registry
Not yet recruiting NCT06412614 - Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
Terminated NCT00622687 - Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis Phase 2
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A